Cargando…

Immune effects of 5-fluorouracil: Ambivalence matters

Cytotoxic anticancer drugs can promote antitumor immune responses. The anticancer activity of 5-fluorouracil (5FU) relies on the restoration of T-cell immunity following the elimination of myeloid-derived suppressor cells (MDSCs). We have recently discovered that the 5FU-driven activation of the NLR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghiringhelli, François, Bruchard, Melanie, Apetoh, Lionel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661151/ https://www.ncbi.nlm.nih.gov/pubmed/23802066 http://dx.doi.org/10.4161/onci.23139

Ejemplares similares

Immune ambivalence: The schizophrenic bleomycin
por: Mignot, Grégoire, et al.
Publicado: (2013)

Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells
por: Bugaut, Hélène, et al.
Publicado: (2013)

Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
por: Thibaudin, Marion, et al.
Publicado: (2023)

Targeting coagulation to unlock antitumor immunity?
por: Galmiche, Antoine, et al.
Publicado: (2022)

Dacarbazine mediates antimelanoma effects via NK cells
por: Hervieu, Alice, et al.
Publicado: (2013)

MAPK signaling regulates the efficacy of chemoimmunotherapy
por: Ghiringhelli, François
Publicado: (2022)

Induction of pyroptosis in colon cancer cells by LXRβ
por: Rébé, Cédric, et al.
Publicado: (2015)

LPCAT2 controls chemoresistance in colorectal cancer
por: Cotte, Alexia Karen, et al.
Publicado: (2018)

Hormesis in cancer immunology: Does the quantity of an immune reactant matter?
por: Pearce, Oliver MT, et al.
Publicado: (2014)

Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response
por: Geindreau, Mannon, et al.
Publicado: (2021)

Is tumor (R)ejection by the immune system the “5th R” of radiobiology?
por: Golden, Encouse B, et al.
Publicado: (2014)

Predicting responses to chemotherapy in the context that matters - the patient
por: Moreno-Gonzalez, Alicia, et al.
Publicado: (2015)

Cancer neoantigens and immunogenicity: mutation position matters
por: Capietto, Aude-Hélène, et al.
Publicado: (2020)

Annotation matters: validating the discovery of cancer drivers
por: Rodríguez-Martínez, Marta, et al.
Publicado: (2020)

DNA methylation markers for breast cancer prognosis: Unmasking the immune component
por: Dedeurwaerder, Sarah, et al.
Publicado: (2012)

Deciphering the Roles of Innate Lymphoid Cells in Cancer
por: Bruchard, Melanie, et al.
Publicado: (2019)

Engineering effective T-cell based antitumor immunity
por: Gruber, Thomas, et al.
Publicado: (2013)

Regulation of T cell antitumor immune response by tumor induced metabolic stress
por: Chalmin, Fanny, et al.
Publicado: (2018)

“Stealth” tumors: Breast cancer cells shun NK-cells anti-tumor immunity
por: Mamessier, Emilie, et al.
Publicado: (2012)

The anticancer effects of HDAC inhibitors require the immune system
por: West, Alison C, et al.
Publicado: (2014)

Opposing effects of androgen ablation on immune function in prostate cancer
por: Tang, Shuai, et al.
Publicado: (2012)

Motolimod effectively drives immune activation in advanced cancer patients
por: Dietsch, Gregory N.
Publicado: (2016)

Speed matters: How subtle changes in DNA end resection rate affect repair
por: Huertas, Pablo, et al.
Publicado: (2015)

BORA-dependent PLK1 regulation: A new weapon for cancer therapy?
por: Cirillo, Luca, et al.
Publicado: (2016)

The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects
por: West, Alison C., et al.
Publicado: (2012)

FOXP3-specific immunity
por: Andersen, Mads Hald
Publicado: (2013)

The ART of tumor immune escape
por: Wennerberg, Erik, et al.
Publicado: (2022)

The CCL5/CCR5 axis promotes metastasis in basal breast cancer
por: Velasco-Velázquez, Marco, et al.
Publicado: (2013)

Glycan-mediated modification of the immune response
por: Madsen, Caroline B., et al.
Publicado: (2013)

Retinoic acid on stage in antitumor immunity
por: Guo, Yanxia, et al.
Publicado: (2013)

The aryl hydrocarbon receptor in tumor immunity
por: Platten, Michael, et al.
Publicado: (2012)

Polyamine blockade promotes antitumor immunity
por: Hayes, Candace S, et al.
Publicado: (2014)

The immune response in HPV(+) oropharyngeal cancer
por: King, Emma V, et al.
Publicado: (2014)

The colorectal cancer immune paradox revisited
por: Angelova, Mihaela, et al.
Publicado: (2015)

Immune-mediated tumor evolution: Nanog links the emergence of a stem like cancer cell state and immune evasion
por: Mao, Chih-Ping, et al.
Publicado: (2014)

Prognostic value of the immune microenvironment in lung adenocarcinoma
por: Kadota, Kyuichi, et al.
Publicado: (2013)

Catechins and antitumor immunity: Not MDSC’s cup of tea
por: Santilli, Giorgia, et al.
Publicado: (2013)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

Crucial role of inflammatory monocytes in antitumor immunity
por: Pommier, Arnaud, et al.
Publicado: (2013)

STATing the importance of immune modulation by platinum chemotherapeutics
por: Hato, Stanleyson V., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_erh32up89s8ie87mfm9uue6j35